ALX ONCOLOGY HOLDINGS INC

Clinical-stage firm developing CD47 inhibitors for hematologic and solid tumors.

ALXO | US

Overview

Corporate Details

ISIN(s):: US00166B1052
LEI:
Country:: United States of America
Address:: 323 ALLERTON AVENUE, 94080 SOUTH SAN FRANCISCO
Website:: https://alxoncology.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on developing therapies that harness the immune system to combat cancer. The company's lead therapeutic candidate, evorpacept, is a next-generation CD47 checkpoint inhibitor designed to block a key signal that cancer cells use to evade immune detection. ALX Oncology is advancing evorpacept in multiple clinical trials as a potential cornerstone therapy for use in combination with other anti-cancer agents. The company's development pipeline targets a broad range of hematologic malignancies and solid tumors, with the goal of improving upon current and future standards of care for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALX ONCOLOGY HOLDINGS INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALX ONCOLOGY HOLDINGS INC

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALX ONCOLOGY HOLDINGS INC via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Human Stem Cells Institute PJSC A biotech investor developing gene therapy, regenerative medicine, and genetic services.	Russian Federation	ISKJ
HUMASIS CO., LTD. Develops & manufactures rapid in-vitro diagnostic test kits & instruments for global POCT markets.	South Korea	205470
Humedix Co., Ltd. Develops hyaluronic acid-based pharma, aesthetics, medical devices, and offers CMO services.	South Korea	200670
HUONS CO., LTD. Global healthcare company providing pharmaceuticals, medical devices, and wellness products.	South Korea	243070
Huons Global Co., Ltd. Develops pharmaceuticals, medical devices, cosmetics, and health foods for the global market.	South Korea	084110
Hutchmed (China) Limited	Hong Kong	HCM
HUTCHMED (China) Ltd Develops and commercializes targeted therapies for cancer and immunological diseases worldwide.	United States of America	HCM
HWAIL PHARM. CO., LTD Develops and manufactures APIs, finished drugs, and functional ingredients for healthcare.	South Korea	061250
Hyloris Pharmaceuticals SA A biopharma company optimizing existing drugs for unmet needs via abbreviated pathways.	Belgium	HYL
HYUNDAI BIOLAND Co.,Ltd. Develops natural biomaterials for cosmetics, nutraceuticals, and regenerative medicine globally.	South Korea	052260